Beta Drugs Ltd - Stock Valuation and Financial Performance

BSE: 0 | NSE: BETA | Pharmaceuticals & Drugs | Small Cap

BSE Share Price
Not Listed

DeciZen - make an informed investing decision on Beta Drugs

Overall Rating
Bole Toh

1. Quality

2. Valuation

Undervalued

3. Price Trend

Beta Drugs stock performance -

mw4me loader
P/E Ratio (SA):
85.20
Market Cap:
1,869.1 Cr.
52-wk low:
0
52-wk high:
0

Is Beta Drugs Ltd an attractive stock to invest in?

1. Is Beta Drugs Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Beta Drugs Ltd is a good quality company.

2. Is Beta Drugs Ltd undervalued or overvalued?

The key valuation ratios of Beta Drugs Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is Beta Drugs Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Beta Drugs Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

10 Year X-Ray of Beta Drugs:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Beta Drugs Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
ROCE % -2.6%21.9%48.9%28.6%18.4%16.9%15.9%26.9%27.9%27.3%-
Value Creation
Index
-1.20.62.51.10.30.20.10.91.01.0-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 0.326.441.750.658.165.379.5125158198198
Sales YoY Gr.-10,046.2%57.9%21.4%14.8%12.5%21.7%57.1%26.5%25.2%-
Adj EPS -0.21.97.88.59.27.47.314.819.622.822.8
YoY Gr.-NA309.5%9.1%8.6%-20.2%-1.2%103.9%32.1%16.6%-
BVPS (₹) 10.621.810.23846.958.76680.6100.1120.7120.7
Adj Net
Profit
-0.11.14.67.487.1714.318.821.922
Cash Flow from Ops. 1.4-0.44.717.17.76.111.618.810.221.2-
Debt/CF from Ops. 3.4-22.51.70.511.50.50.40.60.3-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 109%27.8%35.5%25.2%
Adj EPS NA19.9%46.4%16.6%
BVPS31.1%20.8%22.3%20.5%
Share Price - 85.4% 48.8% 88.1%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
Return on
Equity %
-18.369.411237.721.714.611.720.221.720.718.9
Op. Profit
Mgn %
2.511.418.720.418.41819.320.219.817NAN
Net Profit
Mgn %
-43.54.311.114.513.710.88.811.411.911.111.1
Debt to
Equity
4.53.81.40.20.20.20.10.10.10.1-
Working Cap
Days
1,67565991381802111961491571700
Cash Conv.
Cycle
354226476373664149510

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 35.49%

Net Profit is growing at healthy rate in last 3 years 46.42%

Return on Equity has declined versus last 3 years average to 18.90%

Sales growth is not so good in last 4 quarters at 0.00%

Latest Financials - Beta Drugs Ltd.

Standalone Consolidated
TTM EPS (₹) 22.8 37.9
TTM Sales (₹ Cr.) 198 296
BVPS (₹.) 120.7 163.4
Reserves (₹ Cr.) 106 148
P/BV 16.11 11.90
PE 85.20 51.30
From the Market
52 Week Low / High (₹) 0.00 / 0.00
All Time Low / High (₹) - / -
Market Cap (₹ Cr.) 1,869
Equity (₹ Cr.) 9.6
Face Value (₹) 10
Industry PE 45.9

Management X-Ray of Beta Drugs:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Beta Drugs

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Sales0264251586579125158198
Operating Expenses 0233441485464100127164
Manufacturing Costs0016789121517
Material Costs01524273035437183112
Employee Cost 034124571011
Other Costs 0556877101824
Operating Profit 0379101215253134
Operating Profit Margin (%) 2.5%11.4%17.5%18.7%17.8%18.0%19.3%20.2%19.8%17.0%
Other Income 0000001112
Interest 0111111011
Depreciation 0112235565
Exceptional Items 0000000000
Profit Before Tax 01577910202529
Tax 0010023668
Profit After Tax 0147877141922
PAT Margin (%) -43.5%4.3%10.2%13.4%13.3%10.9%8.8%11.4%11.9%11.1%
Adjusted EPS (₹)-0.21.97.27.88.97.47.314.819.622.8
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24

Equity and Liabilities

Shareholders Fund 126334156637796116
Share Capital 111991010101010
Reserves 015243247546887106
Minority Interest0000000000
Debt4886674544
Long Term Debt4443533544
Short Term Debt0444141000
Trade Payables247610913202336
Others Liabilities 01349108121420
Total Liabilities 8152350668389115137175

Fixed Assets

Gross Block191118194243546065
Accumulated Depreciation123571015202529
Net Fixed Assets17813123228343536
CWIP 60011502000
Investments 0000267776
Inventories132366881422
Trade Receivables041114172121314450
Cash Equivalents 00012348161827
Others Assets0026101415192133
Total Assets 8152350668389115137175

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Cash Flow From Operating Activity 105178612191021
PBT 01577910202529
Adjustment 0221522430-6
Changes in Working Capital 1-3-3-5-1-4-2-5-15-2
Tax Paid 0000000000
Cash Flow From Investing Activity -6-2-2-11-16-14-3-13-6-11
Capex -6-2-2-8-15-8-3-10-7-6
Net Investments 0000-2-50001
Others 000-30-21-31-5
Cash Flow From Financing Activity 43-35-19-41-2-1
Net Proceeds from Shares 1008090000
Net Proceeds from Borrowing 00-1-13-102-10
Interest Paid 0-1-1-1-1-1-10-1-1
Dividend Paid 0000000000
Others 33-10-23-3-100
Net Cash Flow 00012-914729
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Ratios
ROE (%)-18.2869.39103.2234.732114.6311.6420.2321.6620.67
ROCE (%)-2.6121.9248.9128.6318.4216.8515.9126.9127.9327.27
Asset Turnover Ratio0.062.272.171.391.010.880.921.231.261.27
PAT to CFO Conversion(x)N/A01.252.4310.861.711.360.530.95
Working Capital Days
Receivable Days25631659010010796768787
Inventory Days1,093292319293532242633
Payable Days2,8287585889810295859496

Beta Drugs Ltd Stock News

Beta Drugs Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Beta Drugs on 01-Jan-1970 05:30 is ₹0.00.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 01-Jan-1970 05:30 the market cap of Beta Drugs stood at ₹1,869.1.
The latest P/E ratio of Beta Drugs as of 01-Jan-1970 05:30 is 85.20.
The latest P/B ratio of Beta Drugs as of 01-Jan-1970 05:30 is 16.11.
The 52-week high of Beta Drugs is ₹0.00 and the 52-week low is ₹0.00.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Beta Drugs is ₹197.6 ( Cr.) .

About Beta Drugs Ltd

No data to display
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.